Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 6

1.

A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.

Klotz LH, McNeill IY, Kebabdjian M, Zhang L, Chin JL; Canadian Urology Research Consortium.

Eur Urol. 2013 May;63(5):927-35. doi: 10.1016/j.eururo.2012.09.007. Epub 2012 Sep 11.

PMID:
23040208
[PubMed - indexed for MEDLINE]
2.

Bone metastases and bone loss medical treatment in prostate cancer patients.

Safriadi F.

Acta Med Indones. 2013 Jan;45(1):76-80. Review.

PMID:
23585414
[PubMed - indexed for MEDLINE]
Free Article
3.

[Treatment effect of breast cancer and prostate cancer on bone].

Varsavsky M, Guadalix Iglesias S.

Med Clin (Barc). 2013 Feb 16;140(4):164-8. doi: 10.1016/j.medcli.2012.05.025. Epub 2012 Jul 28. Review. Spanish.

PMID:
22841464
[PubMed - indexed for MEDLINE]
4.

Complications of androgen deprivation therapy: prevention and treatment.

Holzbeierlein JM, Castle E, Thrasher JB.

Oncology (Williston Park). 2004 Mar;18(3):303-9; discussion 310, 315, 319-21. Review.

PMID:
15065701
[PubMed - indexed for MEDLINE]
5.

Bone complications of cancer treatment in the elderly.

Balducci L.

Oncology (Williston Park). 2010 Jul;24(8):741-7. Review.

PMID:
20718254
[PubMed - indexed for MEDLINE]
6.

Laryngeal ulceration and hemoptysis secondary to inadvertent alendronate overdose: case report and review of the literature.

Hanna J, Bee J, Sataloff RT.

Ear Nose Throat J. 2012 Nov;91(11):484-5. Review.

PMID:
23288794
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk